胸苷激酶1(TK1)作为肿瘤蛋白质组学生物标志物的系统综述
本文系统综述了血清胸苷激酶1(TK1)作为细胞增殖标志物在肿瘤实验室医学中的诊断与预后应用。综述纳入108项研究,重点分析TK1检测系统从放射性同位素活性法向酶联免疫分析法(尤其双单克隆ELISA)的演变,并汇总其在多种恶性肿瘤中的分析性能与临床证据。
要点
- 双单克隆ELISA检测TK1的检测限为0.12 ng/mL,精密度系数5-15%。
- 超过15,000例患者证据显示血清TK1高水平与肿瘤负荷、分期及治疗反应相关。
- TK1与CEA、CA19-9、CYFRA21-1联合可提高诊断准确性,多标志物组合AUC范围0.79-0.96。
核心结论
- 血清TK1是细胞增殖的显著标志物,在肿瘤实验室医学中具有明确的诊断和预后用途。
研究设计与样本
- 系统综述,基于对主要科学数据库的系统检索,纳入108项高质量研究。
- 重点考察TK1的生化特性及其在肿瘤治疗中的应用。
主要发现
- 现代双单克隆ELISA系统检测限为0.12 ng/mL,精密度系数5-15%,在多种恶性肿瘤中诊断灵敏度为59-95%。
- 超过15,000例患者队列显示血清TK1高水平与肿瘤负荷、疾病分期及治疗反应重要相关,涵盖血液肿瘤和实体瘤。
- TK1与CEA、CA19-9、CYFRA21-1联合检测可提高诊断准确性,多标志物组合AUC范围为0.79-0.96。
- 预后分析表明TK1还可作为其他类型癌症的生存预测因子。
关键数值与推荐
- 双单克隆ELISA检测限0.12 ng/mL,精密度系数5-15%,多种恶性肿瘤诊断灵敏度59-95%。
- TK1联合CEA、CA19-9、CYFRA21-1的多标志物组合AUC范围0.79-0.96。
临床怎么用
- TK1检测系统已转向适用于日常临床化学实验室的酶联免疫分析法,而非放射性同位素活性法。
- 血清TK1水平可用于评估肿瘤负荷、疾病分期及治疗反应,并可与已知标志物联合提高诊断准确性。
局限性
- 实施难点主要包括检测标准化、平台特异性参考区间的建立以及质量保证程序的提供。
- 需进一步开展实验室医学研究以提高检测一致性、自动化程度及将自动化系统整合至系统化检测中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Serum thymidine kinase 1 (TK1) is a notable biomarker of cellular increase that has well-determined diagnostic and prognostic uses in oncological laboratory medicine. This review examines the evolution of TK1 detection systems that now use enzyme-linked immunoassays rather than radioisotope-based activity assays to detect TK1, which are suitable for daily clinical chemistry laboratories. Modern dual-monoclonal ELISA systems have higher analytical capabilities, with a detection limit of 0.12 ng/mL and a precision coefficient of 5-15 % and a diagnostic sensitivity of 59-95 % in diverse malignancies. A cohort of over 15,000 patients has provided clinical evidence showing an important correlation between high levels of serum TK1 and tumor burden, disease stage, and treatment response in hematology and solid tumors. Comparative analyses revealed that combining TK1 with known biomarkers (CEA, CA19-9, and CYFRA21-1) increased the accuracy of diagnosis. This is especially so in multimarker panels, which have an range of 0.79-0.96 in AUC. The usefulness of TK1 as an early warning for cancer has been established in population screening in a study of more than 47, 000 individuals with a diagnostic accuracy of 96. TK1 has also been identified as a predictor of survival in other types of cancers through prognostic analyses. This is a systematic review of the high-quality results of 108 studies selected on the basis of a systematic search of the scientific databases of the most important literature, where specific attention was paid to the biochemical properties of thymidine kinase 1 and its use in cancer treatment. The main areas of implementation difficulty are assay standardization, platform-specific reference interval creation, and provision of quality assurance procedures. Further laboratory medical studies must be conducted to improve the uniformity of the tests, automation, and integration of automated systems into systematic testing to clarify the use of TK1 in precise cancer diagnosis.
引用
- Samuel VP, Afzal M, Babu MA, et al. Thymidine kinase 1 (TK1) as a proteomic biomarker in cancer. Clin Chim Acta. 2025. PMID: 41183606. doi:10.1016/j.cca.2025.120696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。